| Investor in | Shire plc |
| Investment of | Akili Interactive |
| Start Date | 2013-00-00 |
| Notes | In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of the Project:EVO™ADHD cognitive measurement product in pediatric ADHD. |